Studies iu this laboratory have demonstrated varying responses in heart rate during levarterenol-induced hypertension. A decreased bradycrotic response did not seem to depend on the age of the patient, the control level of arterial pressure or the percentage increase in mean arterial pressure. The present study was designed to evaluate the factors which govern the changes in heart rate during levarterenol infusion. P ATIENTS studied iu this laboratory have demonstrated varying responses in hea.t rate during levarterenol-induced hypertension. All those without obvious cardiovascular disease showed significant bradyeardia, while some patients with an elevated arterial pressure did not. Judson, Epstein, and Wilkins 1 have also noted this decrease in bradycrotic response during levarterenolinduced hypertension in patients with chronic hypertensive disease. The present study was designed to evaluate the relationship of the age of the patient, the initial level of arterial pressure, the per cent increase in arterial pressure, and the presence of arteriosclerosis on the response of the heart rate during levarterenol administration.
Studies iu this laboratory have demonstrated varying responses in heart rate during levarterenol-induced hypertension. A decreased bradycrotic response did not seem to depend on the age of the patient, the control level of arterial pressure or the percentage increase in mean arterial pressure. The present study was designed to evaluate the factors which govern the changes in heart rate during levarterenol infusion. P ATIENTS studied iu this laboratory have demonstrated varying responses in hea.t rate during levarterenol-induced hypertension. All those without obvious cardiovascular disease showed significant bradyeardia, while some patients with an elevated arterial pressure did not. Judson, Epstein, and Wilkins 1 have also noted this decrease in bradycrotic response during levarterenolinduced hypertension in patients with chronic hypertensive disease. The present study was designed to evaluate the relationship of the age of the patient, the initial level of arterial pressure, the per cent increase in arterial pressure, and the presence of arteriosclerosis on the response of the heart rate during levarterenol administration. METHODS One hundred eight patients were studied. Fiftyfive patients were without any manifest cardiovascular disease. Forty-four were young (group 1) and 11 were elderly (group 2). Eleven patients showed clinical evidence of arteriosclerosis with a Received for publication March 4, 1959. normal arterial pressure (group 3). Eleven patients showed evidence of arteriosclerosis with an elevated arterial pressure (group 4). In 16 patients there was an elevated arterial pressure without obvious signs of arteriosclerosis (group 5). Fifteen patients were diagnosed as toxemia of pregnancy (group 6). The presence of the following clinical signs of arteriosclerosis were used to categorize the patients. Historical: cerebral vascular accident, angina or coronary infarction, amputation for gangrene due to arteriosclerosis obliterans, diabetes of at least several years duration. Physical examination : signs of hemiplegia, ophthalmoscopic evidence of arteriovenous compression and/or nicking, diminution or absence of dorsalis pedis or posterior tibial pulsation. Laboratory : x-ray evidence of enlargement or calcification of the thoracic aorta, electrocardiographic evidence of a conduction defect or infarction. None of the patients in the above groups were receiving digitalis, ganglionic blocking agents or atropine derivatives because of the possible interference with levarterenol on the heart rate.
The average ages and arterial pressures of the patients are listed in table 1. None of the patients in groups 1 and 2 demonstrated any of the clinical siftns of arteriosclerosis listed above except for the presence of calcium deposits in the aorta in 2 elderly patients in group 2.
The patients in group 3 were diagnosed as having either generalized arteriosclerosis or arterioselerotic heart disease without hypertension. In no patient was there a history of hypertension. The signs of arteriosclerosis in each patient are noted in table 2.
The 11 patients in group 4 were pntients with hypertensive cardiovascular disease of long standing. The signs of arteriosclerosis in these patients are noted in table 3.
Of the 16 patients in group 5 (elevated arteri:-.] pressure without arteriosclerosis) 7 patients were diagnosed as postpartum hypertension, 7 as essential hypertension, one as acute glonienilonephriti.s .JO.J
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and 1 patient subacute glomerulonephritis. The diagnosis of nephritis was documented by renal biopsy in both instances. In no patient was the duration of hypertension longer than 6 months by history. ]S T one of these patients showed any of the clinical signs of arteriosclerosis noted above.
The criteria for the diagnosis of toxemia in the 15 patients in group 6 include excessive weight gain, edema, proteinuria, and a rise in arterial pressure. Each patient demonstrated at least 2 of these abnormalities. Although the level of arterial pressure in these patients is similar to that noted in group 1, it should be noted that the age group is younger and that there had been a recent rise in arterial pressure during the preceding 4 weeks in each of these patients. None of these patients showed any of the clinical signs of arteriosclerosis noted above.
The patients were in the fasting state and remained in the supine position throughout the experiment. Levarterenol bitartrate (Levophed) was administered as an intravenous infusion in a concentration of 4 /.ig./ml. of 5 per cent dextrose in water. The rate of the infusion was regulated according to the increase in arterial pressure and the decrease in heart rate varied between 4 and 24 jug./min. The end point of the experiment was taken as a rise of arterial pressure in excess of 25 per cent or a decrease in heart rate of more than 10 beats/niin. In those patients in whom one or the other end point was not reached the levarterenol infusion was continued for at least 10 min. The infusion was promptly discontinued, however, if chest pain, headache or extrasystoles occurred. The arterial blood pressure was recorded by the usual auscultatory method. The mean arterial pressure was determined by the formula systolic plus diastolic divided by 2. The blood pressure and heart rate were recorded every 30 sec.
The response of the heart rate following the intravenous administration of 1 mg. of atroplne sulfate was determined in 6 of the young patients without cardiovascular disease (group 1) and in 7 patients with either a long history of hypertension or obvious signs of arteriosclerosis. These latter 7 patients had demonstrated a decreased bradycrotic response during levarterenol but were not included in either group 3 or group 4 because they were also receiving digitalis.
RESULTS
A 38 ± 17 per cent increase in mean arterial pressure in the 44 patients without cardiovascular disease (group 1) was accompanied by an average fall iu heart rate of 21.4 ± 8.0 beats/miu. (table 1) . A decrease in heart rate of at least 12 beats/min. occurred in each patient.
A 16 ± 6.5 per cent increase in mean arterial pressure in the 11 elderly patients without cardiovascular disease (group 2) was accompanied by an average reduction in heart rate of 16 ± 6.7 beats/min. This decrease in heart rate exceeded 10 beats/min. in each patient.
Nine of the 11 patients with arteriosclerosis and a normal arterial pressure (group 3) showed a decreased bradycrotic response during levarterenol infusion. When the group was considered as a whole, a 32 ± 6 per cent increase in mean arterial pressure was accompanied by an average fall in heart rate of 7 ± 4 beats/min. In the 2 patients (R.K., E.M.; table 2) who demonstrated significant bradycardia, there was a reduction of 20 beats/min. in 1 patient and of 12/min. in another. If these 2 patients were excluded, the average change in the heart rate in the remaining 9 patients during levarterenol administration would be 4 ± 2 beats/min.
A 27.4 ± 9 per cent increase in mean arterial pressure in the 11 patients who showed evidence of both hypertension and arteriosclerosis (group 4) was accompanied by an average change in heart rate of 0.8 ± 3.8 beats/min. The increase in heart rate did not exceed 4 beats/min. in any patient in this group.
A 20 ± 9.2 per cent increase in mean arterial pressure in the 16 patients with an elevated arterial pressure with no signs of arteriosclerosis (group 5) was accompanied by an average reduction in heart rate of 19 ± 9 beats/min. A decrease in heart rate of at least 8 beats/min. occurred iu each patient.
A 44 ± 11 per cent increase in mean arterial pressure in the 15 patients with toxemia of pregnancy was accompanied by an average reduction in heart rate of 19 ± 3.6 beats/min. A decrease in heart rate exceeded 14 beats/ min. in each patient in this group.
In the 6 patients without cardiovascular disease the administration of 1 mg. of atro- pine intravenously was associated with an average increase in heart rate of 22.4 ± 6 beats/min. In these patients a 31.3 ± 8 per cent increase in mean arterial pressure witli levarterenol was associated with a 19.6 ± 6 beats/min. decrease in heart iate. In the 7 digitalized patients with cardiovascular disease, 1 mg. of atropine administered intravenously was followed by a 21.4 ± 3 beats/min. increase in heart rate. In these patients a 34.1 ± 6 per cent increase in mean arterial pressure during levarterenol was associated with a 3.4 ± 2 beats/min. decrease in heart rate. DISCUSSION' It has been established that the bradycardia associated with the infusion of levarterenol is of reflex origin mediated through the sinoaortic buffering mechanisms.-The data presented here are in agreement with those of other investigators'-3 who have demonstrated that whereas a rise in arterial pressure is necessary for initiation of the reflex, the per cent increase in mean arterial pressure is not the determining factor which governs the response of the heart rate.
A decrease in the sensitivity of the buffer reflexes during levarterenol infusion might accompany a defect either in the afferent or efferent limb of the reflex or in the walls of the aortic arch or carotid sinus. In an attempt to localize the defect in those patients who manifested a decreased bradycrotic response during levarterenol, atropine was administered. The production of tachycardia by atropine in all patients, whether they demonstrated bradyeardia during levarterenol or not (even though some were also receiving digitalis), indicates the intactness of the vagus nerve.
In a further attempt to localize the defect responsible for the decreased bradycrotic re- spouse during levarterenol in patients in groups 3 and 4, the response of the heart rate to external massage of the carotid sinus was studied. This procedure produced more than a 10 beat/min. slowing of the heart rate in 3 of the 4 patients with obvious signs of arteriosclerosis (group 3) who failed to develop significant bradycardia during levarterenol infusion. Unfortunatety the behavior of the heart rate during external massage of the carotid sinus was not tested routinely.
The studies of Loeffler, Lotteubach and Scharf 4 who demonstrated a discrepancy in the sensitivity of the carotid sinus to an increase in endosinus pressure and external massage, the common clinical observation of increased carotid-sinus sensitivity in elderly sclerotic patients/' and the pathologic find-ings ol' Suiidcr-Plassinau, 0 all support the finding that the afferent nerves of the sinoaortic reflex are intact even in the presence of sclerosis in the walls of the aortic arch. All the above would tend to indicate that the defect in the sinoaortic reflex in the patients in groups 3 and 4 is either a decrease in sensitivity of the recepto:s themselves and/or a decrease in the intensity oi the stimulus, e.g., a decreased expansion of the vessel wall. Xo differentiation between these two possibilities can be made from the data presented.
Tt has been demonstrated that large vessels are less elastic at higher levels of arterial pressure. 7 Such an observation cannot be offered as an explanation for the varying respouses in heart rate during levarterenol from the data presented here, for the initial level of arterial pressure is not significantly different in those patients in whom the normal bradycardia was observed than in those who failed to develop a significant bradycardia during levarterenol. Further, it might be postulated that a decrease in the sensitivity in the carotid sinus reflex might be associated with the medial degeneration of the elastic fibers in the walls of the large arteries noted with age. The production of bradycardia during levarterenol infusion in the 11. elderly normal subjects (group 2) seems to rule out the importance of age, at least as the sole determining factor. The factors responsible for the decreased bradycrotic response during levarterenol infusion in the patients in groups 3 and 4 could not be demonstrated. It would seem, however, that this result must be related in some way to arteriosclerosis, of -which each of these patients demonstrated several clinical signs (tables 2 and 3). Although these rlata furnish no proof, a possible explanation for the decreased bradycrotic response during levarterenol infusion in the patients in groups 2 and 3 might be the presence of an arteriosclerotic process in the walls of the aorta. Such sclerotic changes could prevent the expansion of the walls of the vessels in response to an increase in the endosinus pressure during levarterenol infusion. This reasoning is in accord with the animal experiments of Ilauss, Asteroth. and Kreuziger 8 who have conclusively demonstrated that prevention of expansion of the sinus by either a F1XXERTY, TUCKMAX, HAJJAK plaster of Paris cast or lead rings abolishes the sinus reflex induced by a rise in endosinus pressure.
SUMMARY
Patients studied in this laboratory have demonstrated varying responses in heart rate during levarterenol-induced hypertension. An increase in the mean arterial pressure was associated with bradycardia in 44 young patients and in 11 elderly patients without any evidence of cardiovascular disease, in 16 patients with elevated arterial pressure without obvious signs of arteriosclerosis and in 15 patients with toxemia of pregnancy. On the other hand, a decreased bradycrotie response was noted when the arterial pressure was increased in 11 arteriosclerotic patients with normal arterial pressure and 10 arteriosclerotic patients with an elevated arterial pressure.
These data demonstrate that the decreased bradycrotie response during levarterenol was not dependent on the age of the patient, the initial level of arterial pressure or the percentage increase in mean arterial pressure.
The factors responsible for the decreased bradycrotic response during levarterenol could not be demonstrated. It would seem, however, that such responses were related in some way to sclerosis since several clinical signs of arteriosclerosis existed in each of the patients who demonstrated this decreased bradycrotic response during levarterenol.
SUMMARIO ix IXTERLINGUA
Le patientes studiate a iste laboratorio ha monstrate varie responsas de frequentia cardiac al hypertension inducite per levarterenol. Un augmento del tension arterial medie esseva associate con bradycardia in 44 patientes de juvene etates e in 11 patientes de etates plus avantiate sin signos evidente de morbo cardiovascular, in 16 patientes con elevation del tension arterial sed sin signos evidente de arteriosclerosis, e in 15 patientes eon toxemia de pregnantia. Del altere latere, un reducite responsa bradycrotic esseva notate post le augmentation del tension arterial in 11 patientes arteriosclerotic con tensiones arterial normal e in 10 patientes arteriosclerotic con tension arterial elevate.
Le datos demonstra que le reducite responsa bradycrotic durante le infusion de levarterenol non dependeva del etate del patiente, del nivello initial del tension arterial, o del augmentation procentual del tension arterial medie.
Le factores responsabile pro le reducite responsa bradycrotic durante le administration de levarterenol non poteva esser identificate. Tamen, il pare que tal responsas esseva relationate in un maniera o un altere con le presentia de sclerosis, proque plure signos clinic de arteriosclerosis esseva notate in omne le patientes qui exhibiva iste reducite responsa bradycrotic durante le infusion de levarterenol.
